Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer

NCT05394831 is registered in ClinicalTrials.gov with J Ints Bio as lead sponsor.

NCT NCT05394831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer
Lead sponsor
J Ints Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 30, 2023
Completion date
September 30, 2026
Enrollment
150 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutant advanced non-small cell lung cancer